News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
160 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37190)
2018 (39122)
2019 (51337)
2020 (57666)
2021 (58724)
2022 (53929)
2023 (42568)
2024 (37443)
2025 (33088)
2026 (1421)
Month
January (1421)
Day
1 (17)
2 (20)
5 (162)
6 (203)
7 (146)
8 (247)
9 (158)
12 (234)
13 (160)
14 (74)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
Day
1
2
5
6
7
8
9
12
13
14
obesity
JPM26: Novartis Doesn’t Have a GLP-1. They Don’t Miss It In a World Of Me-Toos
Speaking to
BioSpace
at the J.P. Morgan Healthcare Conference, Novartis’ chief dealmaker Ronny Gal explains why the Swiss pharma hasn’t acquired a GLP-1, and why it probably won’t.
January 13, 2026
·
3 min read
·
Annalee Armstrong
Business
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff
Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted a 2028 launch. CEO Albert Bourla explained the pharma’s strategy at J.P. Morgan on Monday.
January 13, 2026
·
3 min read
·
Nick Paul Taylor
Press Releases
Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer
January 13, 2026
·
6 min read
Press Releases
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026
January 13, 2026
·
9 min read
Press Releases
ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM
January 13, 2026
·
3 min read
Press Releases
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
January 13, 2026
·
15 min read
Press Releases
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
January 13, 2026
·
10 min read
Press Releases
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
January 13, 2026
·
9 min read
Press Releases
Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531)
January 13, 2026
·
6 min read
Press Releases
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
January 13, 2026
·
10 min read
Previous
2 of 16
Next